Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer

LOS ANGELES--(BUSINESS WIRE)--Overall survival results from Puma Biotechnology's Phase III ExteNET trial were published online in Clinical Breast Cancer.

Click to view original post